| Style | Citing Format |
|---|---|
| MLA | Dashtikhavidaki S, Abdollahi M. "Intravitreal Administration of Bevacizumab: Pros and Cons." DARU# Journal of Pharmaceutical Sciences, vol. 23, no. 1, 2015, pp. -. |
| APA | Dashtikhavidaki S, Abdollahi M (2015). Intravitreal Administration of Bevacizumab: Pros and Cons. DARU# Journal of Pharmaceutical Sciences, 23(1), -. |
| Chicago | Dashtikhavidaki S, Abdollahi M. "Intravitreal Administration of Bevacizumab: Pros and Cons." DARU# Journal of Pharmaceutical Sciences 23, no. 1 (2015): -. |
| Harvard | Dashtikhavidaki S, Abdollahi M (2015) 'Intravitreal Administration of Bevacizumab: Pros and Cons', DARU# Journal of Pharmaceutical Sciences, 23(1), pp. -. |
| Vancouver | Dashtikhavidaki S, Abdollahi M. Intravitreal Administration of Bevacizumab: Pros and Cons. DARU# Journal of Pharmaceutical Sciences. 2015;23(1):-. |
| BibTex | @article{ author = {Dashtikhavidaki S and Abdollahi M}, title = {Intravitreal Administration of Bevacizumab: Pros and Cons}, journal = {DARU# Journal of Pharmaceutical Sciences}, volume = {23}, number = {1}, pages = {-}, year = {2015} } |
| RIS | TY - JOUR AU - Dashtikhavidaki S AU - Abdollahi M TI - Intravitreal Administration of Bevacizumab: Pros and Cons JO - DARU# Journal of Pharmaceutical Sciences VL - 23 IS - 1 SP - EP - PY - 2015 ER - |